Aminocaproic acid (Amicar) as an alternative to aprotinin (Trasylol) in liver transplantation

Transplantation Proceedings

Volumn 46, Issue 5, 2014, Pages 1393-1399

  Mangus, R S ^a   Kinsella, S B ^a   Fridell, J A ^a   Kubal, C A ^a   Lahsaei, P ^a   Mark, L O ^a   Tector, A J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; DRUG MEGADOSE; FEMALE; GRAFT FAILURE; HUMAN; INTRAOPERATIVE PERIOD; LIVER GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AMINOCAPROIC ACID; APROTININ; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84902437853     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.04.006     Document Type: Article

References (38)

1. P.E. Frasco, K.A. Poterack, J.G. Hentz, and D.C. Mulligan A comparison of transfusion requirements between living donation and cadaveric donation liver transplantation: relationship to model of end-stage liver disease score and baseline coagulation status Anesth Analg 101 2005 30 37
2. W.L. Shan, J. Barkun, P. Metrakos, J. Tchervenkov, and S.B. Backman Blood product use during orthotopic liver transplantation Can J Anaesthesia 51 2004 1045 1046
3. L. Massicotte, M.P. Sassine, S. Lenis, and A. Roy Transfusion predictors in liver transplant Anesth Analg 98 2004 1245 1251
4. Y. Ozier, F. Pessione, E. Samain, F. Courtois French Study Group on Blood Transfusion in Liver Transplantation Institutional variability in transfusion practice for liver transplantation Anesth Analg 97 2003 671 679
5. A. Steib, G. Freys, C. Lehmann, C. Meyer, and G. Mahoudeau Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict Can J Anaesth 48 2001 1075 1079
6. R.S. Mangus, S.B. Kinsella, M.M. Nobari, J.A. Fridell, R.M. Vianna, and E.S. Ward et al. Predictors of blood product use in orthotopic liver transplantation using the piggyback hepatectomy technique Transplant Proc 39 2007 3207 3213
7. C. Lentschener, K. Roche, and Y. Ozier A review of aprotinin in orthotopic liver transplantation: can its harmful effects offset its beneficial effects? Anesth Analg 100 2005 1248 1255
8. A. De Gasperi, F. Baudo, and L. De Carlis Recombinant FVII in orthotopic liver transplantation (OLT): a preliminary single centre experience Intensive Care Med 31 2005 315 316
9. R.A. Schroeder, B.H. Collins, E. Tuttle-Newhall, K. Robertson, J. Plotkin, and L.B. Johnson et al. Intraoperative fluid management during orthotopic liver transplantation J Cardiothorac Vasc Anesth 18 2004 438 441
10. R.J. Porte, H.G. Hendriks, and M.J. Slooff Blood conservation in liver transplantation: the role of aprotinin J Cardiothorac Vasc Anesth 18 2004 31S 37S
11. J.Y. Findlay, S.R. Rettke, M.H. Ereth, D.J. Plevak, R.A. Krom, and R.P. Kufner Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study Liver Transplant 7 2001 802 807
12. R.J. Porte, I.Q. Molenaar, B. Begliomini, T.H. Groenland, A. Januszkiewicz, and L. Lindgren et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group Lancet 355 2000 1303 1309
13. E. Ramos, A. Dalmau, A. Sabate, C. Lama, L. Llado, and J. Figueras et al. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them Liver Transplant 9 2003 1320 1327
14. E. Bennett-Guerrero, D.E. Feierman, G.R. Barclay, M.K. Parides, P.A. Sheiner, and M.G. Mythen et al. Preoperative and intraoperative predictors of postoperative morbidity, poor graft function, and early rejection in 190 patients undergoing liver transplantation Arch Surg 136 2001 1177 1183
15. T.V. Cacciarelli, E.B. Keeffe, D.H. Moore, W. Burns, S. Busque, and W. Concepcion et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation Arch Surg 134 1999 25 29
16. J.C. Palomo Sanchez, C. Jimenez, E. Moreno Gonzalez, I. Garcia, F. Palma, and C. Loinaz et al. Effects of intraoperative blood transfusion on postoperative complications and survival after orthotopic liver transplantation Hepatogastroenterology 45 1998 1026 1033
17. E. Mor, I. Jennings, T.A. Gonwa, M.J. Holman, J. Gibbs, and H. Solomon et al. The impact of operative bleeding on outcome in transplantation of the liver Surg Gynecol Obstet 176 1993 219 227
18. S. Aytac, C. Turkay, N. Bavbek, and A. Kosar Hemostasis and global fibrinolytic capacity in chronic liver disease Blood Coagul Fibrinolysis 18 2007 623 626
19. D. Ferro, A. Celestini, and F. Violi Hyperfibrinolysis in liver disease Clin Liver Dis 13 2009 21 31
20. L. Biland, F. Duckert, S. Prisender, and D. Nyman Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen Thromb Haemost 39 1978 646 656
21. J. Gram, J. Jespersen, S. Ingeberg, K.D. Bentsen, and E. Bach Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease Thromb Res 39 1985 411 417
22. F. Marongiu, A.M. Mamusa, G. Mameli, G. Mulas, A. Solinas, and L. Demelia et al. Alpha 2 antiplasmin and disseminated intravascular coagulation in liver cirrhosis Thromb Res 37 1985 287 294
23. S.F. Stein, and L.A. Harker Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis J Lab Clin Med 99 1982 217 230
24. N.A. Booth, J.A. Anderson, and B. Bennett Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator J Clin Pathol 37 1984 772 777
25. M.R. Nagaoka, M. Kouyoumdjian, and D.R. Borges Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis Liver Int 23 2003 476 483
26. S. Agarwal, K.A. Joyner Jr., and M.W. Swaim Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease Am J Gastroenterol 95 2000 3218 3224
27. J.F. Boylan, J.R. Klinck, A.N. Sandler, R. Arellano, P.D. Greig, and H. Nierenberg et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation Anesthesiology 85 1996 1043 1048 discussion 1030A-31A
28. Y. Kang, J.H. Lewis, A. Navalgund, M.W. Russell, F.A. Bontempo, and L.S. Niren et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation Anesthesiology 66 1987 766 773
29. A. Dalmau, A. Sabate, F. Acosta, L. Garcia-Huete, M. Koo, and T. Sansano et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation Anesth Analg 91 2000 29 34
30. N. Warnaar, S.V. Mallett, and J.R. Klinck et al. Aprotinin and the risk of thrombotic complications after liver transplantation: a retrospective analysis of 1492 patients Liver Transpl 15 2009 747 753
31. I.Q. Molenaar, N. Warnaar, H. Groen, E.M. Tenvergert, M.J. Slooff, and R.J. Porte Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis Am J Transplant 7 2007 185 194
32. R.S. Mangus, J.A. Fridell, R.M. Vianna, M.A. Milgrom, P. Chestovich, and R.K. Chihara et al. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in extended criteria liver donors Liver Transpl 14 2008 365 373
33. R.S. Mangus, J.A. Fridell, R.M. Vianna, A.B. Cooper, D.T. Jones, and A.J. Tector Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma Transplantation 85 2008 1496 1499
34. T.A. Gonwa, L. Jennings, M.L. Mai, P.C. Stark, A.S. Levey, and G.B. Klintmalm Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations Liver Transpl 10 2004 301 309
35. R.S. Mangus, J.A. Fridell, R.M. Vianna, P.Y. Kwo, J.C. Chen, and A.J. Tector Immunosuppression induction with rabbit antithymocyte globulin (rATG) ± rituximab in 1000 liver transplants with long-term follow-up Liver Transpl 18 2012 786 795
36. D.A. Fergusson, P.C. Hebert, C.D. Mazer, S. Fremes, C. MacAdams, J.M. Murkin BART Investigators A comparison of aprotinin and lysine analogues in high-risk cardiac surgery N Engl J Med 358 2008 2319 2331
37. V.W. Xia, and R.H. Steadman Antifibrinolytics in orthotopic liver transplantation: current status and controversies Liver Transplant 11 2005 10 18
38. "European Medicines Agency recommends lifting suspension of aprotinin". European Medicines Agency. 2012-02-17.